![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FNTB |
Gene summary for FNTB |
![]() |
Gene information | Species | Human | Gene symbol | FNTB | Gene ID | 2342 |
Gene name | farnesyltransferase, CAAX box, beta | |
Gene Alias | FPTB | |
Cytomap | 14q23.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P49356 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2342 | FNTB | P65T-E | Human | Esophagus | ESCC | 6.76e-12 | 2.68e-01 | 0.0978 |
2342 | FNTB | P74T-E | Human | Esophagus | ESCC | 1.54e-14 | 4.13e-01 | 0.1479 |
2342 | FNTB | P75T-E | Human | Esophagus | ESCC | 3.35e-20 | 3.46e-01 | 0.1125 |
2342 | FNTB | P76T-E | Human | Esophagus | ESCC | 1.37e-04 | 1.41e-01 | 0.1207 |
2342 | FNTB | P79T-E | Human | Esophagus | ESCC | 2.76e-22 | 3.88e-01 | 0.1154 |
2342 | FNTB | P80T-E | Human | Esophagus | ESCC | 4.91e-10 | 3.76e-01 | 0.155 |
2342 | FNTB | P83T-E | Human | Esophagus | ESCC | 4.27e-16 | 4.21e-01 | 0.1738 |
2342 | FNTB | P84T-E | Human | Esophagus | ESCC | 6.61e-08 | 4.21e-01 | 0.0933 |
2342 | FNTB | P89T-E | Human | Esophagus | ESCC | 4.77e-04 | 3.08e-01 | 0.1752 |
2342 | FNTB | P91T-E | Human | Esophagus | ESCC | 3.83e-14 | 1.06e+00 | 0.1828 |
2342 | FNTB | P107T-E | Human | Esophagus | ESCC | 4.75e-13 | 2.92e-01 | 0.171 |
2342 | FNTB | P128T-E | Human | Esophagus | ESCC | 1.11e-02 | 1.68e-01 | 0.1241 |
2342 | FNTB | P130T-E | Human | Esophagus | ESCC | 9.86e-24 | 4.23e-01 | 0.1676 |
Page: 1 2 3 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa009005 | Esophagus | ESCC | Terpenoid backbone biosynthesis | 20/4205 | 23/8465 | 2.14e-04 | 7.87e-04 | 4.03e-04 | 20 |
hsa0090012 | Esophagus | ESCC | Terpenoid backbone biosynthesis | 20/4205 | 23/8465 | 2.14e-04 | 7.87e-04 | 4.03e-04 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FNTB | SNV | Missense_Mutation | novel | c.725N>G | p.Val242Gly | p.V242G | P49356 | protein_coding | tolerated(0.34) | benign(0.309) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
FNTB | SNV | Missense_Mutation | rs778887316 | c.17N>T | p.Ser6Phe | p.S6F | P49356 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FNTB | SNV | Missense_Mutation | c.731N>A | p.Gly244Glu | p.G244E | P49356 | protein_coding | deleterious(0.02) | benign(0.383) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FNTB | SNV | Missense_Mutation | c.574N>T | p.Leu192Phe | p.L192F | P49356 | protein_coding | tolerated(0.7) | benign(0.161) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FNTB | SNV | Missense_Mutation | c.95N>C | p.Arg32Pro | p.R32P | P49356 | protein_coding | deleterious(0.05) | benign(0.136) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
FNTB | SNV | Missense_Mutation | c.373G>C | p.Asp125His | p.D125H | P49356 | protein_coding | tolerated(0.09) | benign(0.222) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
FNTB | deletion | Frame_Shift_Del | novel | c.1001delN | p.Leu335CysfsTer6 | p.L335Cfs*6 | P49356 | protein_coding | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | ||
FNTB | SNV | Missense_Mutation | novel | c.76N>G | p.Leu26Val | p.L26V | P49356 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FNTB | SNV | Missense_Mutation | rs773699138 | c.946C>T | p.His316Tyr | p.H316Y | P49356 | protein_coding | tolerated(1) | benign(0) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FNTB | SNV | Missense_Mutation | novel | c.625T>G | p.Ser209Ala | p.S209A | P49356 | protein_coding | tolerated(0.17) | benign(0.05) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | lonafarnib | LONAFARNIB | 26033044 | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 249565706 | BMS-214662 | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 249565705 | TIPIFARNIB | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | CHEMBL289228 | TIPIFARNIB | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | TIPIFARNIB | TIPIFARNIB | ||
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 249565708 | ||
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | carboplatin | CARBOPLATIN | 26033044 | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | CP-609,754 | |||
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | paclitaxel | PACLITAXEL | 26033044 | |
2342 | FNTB | DRUGGABLE GENOME, ENZYME, CLINICALLY ACTIONABLE | inhibitor | 178103145 |
Page: 1 2 |